Company Analysis ICU Medical
1. Summary
Advantages
- The stock's return over the last year (-18.99%) is higher than the sector average (-34.84%).
- The company's current efficiency (ROE=-5.76%) is higher than the sector average (ROE=-83.36%)
Disadvantages
- Price (131.95 $) is higher than fair price (57.79 $)
- Dividends (0%) are below the sector average (1.28%).
- Current debt level 39.05% has increased over 5 years from 2.14%.
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| ICU Medical | Healthcare | Index | |
|---|---|---|---|
| 7 days | -0.8% | -6.9% | -0.1% |
| 90 days | -12.6% | -34.2% | 6.8% |
| 1 year | -19% | -34.8% | 10.9% |
ICUI vs Sector: ICU Medical has outperformed the "Healthcare" sector by 15.85% over the past year.
ICUI vs Market: ICU Medical has significantly underperformed the market by -29.88% over the past year.
Stable price: ICUI is not significantly more volatile than the rest of the market on "New York Stock Exchange" over the last 3 months, with typical variations of +/- 5% per week.
Long period: ICUI with weekly volatility of -0.3651% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Above fair price: The current price (131.95 $) is higher than the fair price (57.79 $).
Price is higher than fair: The current price (131.95 $) is 56.2% higher than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (347.23) is higher than that of the sector as a whole (53.16).
P/E vs Market: The company's P/E (347.23) is higher than that of the market as a whole (62.08).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (1.91) is lower than that of the sector as a whole (10.88).
P/BV vs Market: The company's P/BV (1.91) is lower than that of the market as a whole (20.84).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (1.58) is lower than that of the sector as a whole (4.06).
P/S vs Market: The company's P/S indicator (1.58) is lower than that of the market as a whole (16.02).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (118.56) is higher than that of the sector as a whole (16.9).
EV/Ebitda vs Market: The company's EV/Ebitda (118.56) is higher than that of the market as a whole (27.1).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -47.1% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-47.1%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-10.32%).
5.4. ROE
ROE vs Sector: The company's ROE (-5.76%) is higher than that of the sector as a whole (-83.36%).
ROE vs Market: The company's ROE (-5.76%) is lower than that of the market as a whole (43%).
5.5. ROA
ROA vs Sector: The company's ROA (-2.74%) is lower than that of the sector as a whole (6.41%).
ROA vs Market: The company's ROA (-2.74%) is lower than that of the market as a whole (23.28%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (15.68%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (9.2%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '1.28%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.67.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
